BEAT Stock Catalyst: HeartBeam, Inc. Receives FDA Clearance for Cable-Free 12-Lead ECG

HeartBeam, Inc. (Nasdaq: BEAT) announced it has received clearance from the U.S. Food and Drug Administration (FDA) for its first-ever, cable-free synthesized 12-lead electrocardiogram (ECG) device. The device is intended for at-home arrhythmia assessment, offering a non-invasive method for patients to monitor heart activity.

The clearance marks a significant advancement in HeartBeam's product offerings, enabling the company to expand its market reach and provide innovative solutions for cardiac care. With this new device, HeartBeam aims to enhance patient convenience and improve the accuracy of ECG readings outside of clinical settings.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.